Valuation: MacroGenics, Inc.

Market Cap 296M 260M 240M 224M 420M 27.95B 428M 2.88B 1.11B 13.78B 1.11B 1.09B 47.88B P/E 2026 *
-6.95x
P/E 2027 * -3.05x
Enterprise Value 296M 260M 240M 224M 420M 27.95B 428M 2.88B 1.11B 13.78B 1.11B 1.09B 47.88B EV / Sales 2026 *
1.8x
EV / Sales 2027 * 3.14x
Free-Float
96.57%
Yield 2026 *
-
Yield 2027 * -
1 day-2.51%
1 week+12.83%
Current month+12.02%
1 month+2.87%
3 months+47.00%
6 months+187.65%
Current year+189.44%
1 week 4
Extreme 4
5.08
1 month 3.81
Extreme 3.81
5.08
Current year 1.58
Extreme 1.58
5.08
1 year 1.18
Extreme 1.185
5.08
3 years 0.99
Extreme 0.9897
21.88
5 years 0.99
Extreme 0.9897
29.16
10 years 0.99
Extreme 0.9897
36.48
Manager TitleAgeSince
Chief Executive Officer 53 13/08/2025
Director of Finance/CFO 59 01/05/2008
Chief Tech/Sci/R&D Officer 61 -
Director TitleAgeSince
Director/Board Member 73 01/09/2001
Director/Board Member 53 13/08/2025
Director/Board Member 62 01/10/2004
Date Insider Type Main position Quantity % Market Cap.
19/05Free

Director

25,750 0.0405%
19/05Free

Chairman

25,750 0.0405%
19/05Free

Director

25,750 0.0405%
Change 5-day change 1-year change 3-year change Capi.($)
-2.51%+12.83%+255.73%-18.82% 296M
-0.72%+0.28%+62.28%+116.76% 55.35B
+1.58%+14.12%+72.87%+85.18% 51.92B
-0.23%-0.98%-14.12%-16.00% 22.76B
+0.98%+9.05%-0.36%+423.40% 22.64B
-0.18%+7.48%+32.16%-14.07% 17.36B
-2.86%+2.20%+26.47%-35.65% 16.1B
+3.02%+12.74%+143.33%+308.04% 13.96B
+0.68%+2.54%+22.28%+168.03% 13.38B
+1.31%+6.52%+28.62% - 12.27B
Average +0.11%+7.31%+62.92%+112.99% 22.6B
Weighted average by Cap. +0.34%+6.56%+46.94%+120.85%

Financials

2026 *2027 *
Net sales 164M 144M 133M 124M 233M 15.51B 238M 1.6B 618M 7.65B 617M 604M 26.57B 94.26M 82.8M 76.29M 71.33M 134M 8.89B 136M 915M 355M 4.38B 354M 346M 15.24B
Net income -18.31M -16.08M -14.81M -13.85M -25.98M -1.73B -26.46M -178M -68.85M -851M -68.74M -67.24M -2.96B -127M -112M -103M -96.13M -180M -11.99B -184M -1.23B -478M -5.91B -477M -467M -20.53B
Net Debt - -
Logo MacroGenics, Inc.
MacroGenics, Inc. is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its other product candidates are MGD024, retifanlimab, enoblituzumab, and vobramitamab duocarmazine. MGD024 is an investigational, next-generation, bispecific CD123 CD3 DART molecule designed to engage CD3 expressed on immune effector cells, such as T cells.
Employees
293
Date Price Change Volume
25/06/26 USD 4.660 -2.51% 1,125,686
24/06/26 USD 4.780 +1.92% 1,941,778
23/06/26 USD 4.690 +2.40% 1,491,011
22/06/26 USD 4.580 +10.90% 2,039,946
18/06/26 USD 4.130 +4.29% 973,000
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
4.660USD
Average target price
6.750USD
Spread / Average Target
+44.85%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MGNX Stock